Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocept Inc (NQ: BIOC )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biocept Inc

< Previous 1 2 3 Next >
Biocept to Hold Business Strategy Conference Call Today
From Biocept, Inc.
Via Business Wire
Biocept Reports First Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
From Biocept, Inc.
Via Business Wire
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
From Biocept, Inc.
Via Business Wire
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
From Biocept, Inc.
Via Business Wire
Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
From Biocept, Inc.
Via Business Wire
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
From Biocept, Inc.
Via Business Wire
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
From Biocept, Inc.
Via Business Wire
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
From Biocept, Inc.
Via Business Wire
Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
From Biocept, Inc.
Via Business Wire
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
From Biocept, Inc.
Via Business Wire
CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
From Biocept, Inc.
Via Business Wire
Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
From Biocept, Inc.
Via Business Wire
Biocept Reports Third Quarter 2021 Financial Results
From Biocept, Inc.
Via Business Wire
Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
From Biocept, Inc.
Via Business Wire
Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
From Biocept, Inc.
Via Business Wire
Biocept to Present at the LD Micro Main Event on October 13
From Biocept, Inc.
Via Business Wire
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
From Biocept, Inc.
Via Business Wire
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
From Biocept
Via Business Wire
Biocept to Present at Four Virtual Investor Conferences in September
From Biocept
Via Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
From Biocept, Inc.
Via Business Wire
Biocept Reports Second Quarter 2021 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021
From Biocept, Inc.
Via Business Wire
Biocept Names David Karlander as Senior Vice President of Commercial Operations
From Biocept
Via Business Wire
Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells
From Biocept, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.